Dashboard
Manage Tickers

TVTX Travere Therapeutics, Inc.

Nasdaq travere.com


$ 35.18 $ 5.51 (18.58 %)    

Friday, 31-Oct-2025 19:53:06 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 35.16
$ 34.15
$ 31.25 x 35
$ 35.17 x 50
$ 32.11 - $ 35.34
$ 12.91 - $ 35.34
6,250,526
na
3.15B
$ 0.99
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-30-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 05-01-2025 03-31-2025 10-Q
4 02-21-2025 12-31-2024 10-K
5 10-31-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 05-06-2024 03-31-2024 10-Q
8 02-20-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 02-23-2023 12-31-2022 10-K
13 10-27-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 02-24-2022 12-31-2021 10-K
17 10-29-2021 09-30-2021 10-Q
18 07-29-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 03-01-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 07-31-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 02-24-2020 12-31-2019 10-K
25 10-30-2019 09-30-2019 10-Q
26 08-06-2019 06-30-2019 10-Q
27 05-07-2019 03-31-2019 10-Q
28 02-26-2019 12-31-2018 10-K
29 11-01-2018 09-30-2018 10-Q
30 08-03-2018 06-30-2018 10-Q
31 05-01-2018 03-31-2018 10-Q
32 02-27-2018 12-31-2017 10-K
33 11-07-2017 09-30-2017 10-Q
34 08-09-2017 06-30-2017 10-Q
35 05-05-2017 03-31-2017 10-Q
36 03-01-2017 12-31-2016 10-K
37 11-04-2016 09-30-2016 10-Q
38 08-05-2016 06-30-2016 10-Q
39 05-05-2016 03-31-2016 10-Q
40 02-26-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

td-cowen-maintains-buy-on-travere-therapeutics-raises-price-target-to-40
TD Cowen Maintains Buy on Travere Therapeu...
10/31/2025 18:07:59

TD Cowen analyst Tyler Van Buren maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $3...

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
10/31/2025 12:10:20

top-2-health-care-stocks-that-may-fall-off-a-cliff-this-quarter
Top 2 Health Care Stocks That May Fall Off...
10/31/2025 11:55:05

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
10/30/2025 21:07:13

travere-therapeutics-q3-adj-eps-059-sales-164859m-beat-106534m-estimate
Travere Therapeutics Q3 Adj. EPS $0.59, Sa...
10/30/2025 20:02:37

Travere Therapeutics (NASDAQ:TVTX) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of ...

earnings-scheduled-for-october-30-2025
Earnings Scheduled For October 30, 2025
10/30/2025 11:12:06

travere-therapeutics-to-present-11-abstracts-including-a-late-breaking-poster-at-american-society-of-nephrology-kidney-week-2025-in-houston-tx-november-6-9-highlights-including-data-duplex-study-showing-more-filspari-treated-patients-achieved-proteinuria-below-07-gg-compared-with-irbesartan-indicating-reduced-kidney-failure-risk-in-fsgs
Travere Therapeutics To Present 11 Abstrac...
10/17/2025 13:09:42

Late-breaking poster from DUPLEX Study shows more FILSPARI® (sparsentan)-treated patients achieved proteinuria below 0.7 g/g co...

novartis-strengthens-kidney-disease-pipeline-with-promising-data
Novartis Strengthens Kidney Disease Pipeli...
10/16/2025 14:50:29

Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings...

Core News & Articles
10 Health Care Stocks With Whale Alerts In...
09/29/2025 17:35:29

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and...

Core News & Articles
KDIGO 2025 Guidelines Endorse FILSPARI By ...
09/26/2025 07:24:20

FILSPARI (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss

the-analyst-verdict-travere-therapeutics-in-the-eyes-of-9-experts
The Analyst Verdict: Travere Therapeutics ...
09/19/2025 13:01:29

hc-wainwright--co-reiterates-buy-on-travere-therapeutics-maintains-47-price-target
HC Wainwright & Co. Reiterates Buy on Trav...
09/19/2025 12:19:12

HC Wainwright & Co. analyst Joseph Pantginis reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $47 ...

stifel-maintains-hold-on-travere-therapeutics-raises-price-target-to-25
Stifel Maintains Hold on Travere Therapeut...
09/12/2025 14:29:00

Stifel analyst Alex Thompson maintains Travere Therapeutics (NASDAQ:TVTX) with a Hold and raises the price target from $20 t...

wells-fargo-maintains-overweight-on-travere-therapeutics-raises-price-target-to-35
Wells Fargo Maintains Overweight on Traver...
09/11/2025 12:38:37

Wells Fargo analyst Mohit Bansal maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target ...

travere-shares-are-trading-higher-wednesday-whats-going-on
Travere Shares Are Trading Higher Wednesda...
09/10/2025 19:52:26

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/10/2025 17:07:06

hc-wainwright--co-reiterates-buy-on-travere-therapeutics-maintains-47-price-target
HC Wainwright & Co. Reiterates Buy on Trav...
09/10/2025 16:40:59

HC Wainwright & Co. analyst Joseph Pantginis reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $47 ...

daktronics-potbelly-coreweave-gamestop-and-other-big-stocks-moving-higher-on-wednesday
Daktronics, Potbelly, CoreWeave, GameStop ...
09/10/2025 14:56:32

travere-therapeutics-announces-fda-drops-advisory-committee-for-filspari-snda-in-fsgs-pdufa-target-date-set-for-january-13-2026
Travere Therapeutics Announces FDA Drops A...
09/10/2025 11:03:38

Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that the U.S. Food and Drug Administration (FDA) has informed the Com...

hc-wainwright--co-reiterates-buy-on-travere-therapeutics-maintains-47-price-target
HC Wainwright & Co. Reiterates Buy on Trav...
09/03/2025 14:41:49

HC Wainwright & Co. analyst Joseph Pantginis reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $47 ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION